Ace Blend Raises $9.91M as Nutrition Startup Reports 300% Growth

Indian nutrition startup Ace Blend has raised $9.91 million in a Series A2 funding round led by 3one4 Capital, with existing investor Fireside Ventures increasing its investment. The company plans to use the fresh capital to support research-led product development and introduce new nutrition formats.

The funding comes as Ace Blend reports strong business growth. According to the company, it grew 300% in FY26, while more than 46% of its customers returned to make repeat purchases. These figures suggest growing demand for its nutritional products, although the source does not specify the revenue base or the period used to calculate repeat purchases.

Fireside Ventures previously led Ace Blend's $3.3 million pre-Series A round. Its participation in the latest financing represents a further investment in the company's approach to evidence-based nutrition.

From a nutrition business to a research-led product portfolio

Founded by Shivam Hingorani, Ace Blend began selling products in 2018. Saif Mehkri joined as co-founder in 2022, bringing nearly three decades of experience in the nutrition industry.

The company develops nutritional products using clinical evidence to guide ingredient selection, dosages and delivery methods. Its portfolio spans several consumer health categories, including heart health, immunity, sleep, recovery and brain health.

Rather than focusing solely on product marketing, Ace Blend operates an integrated supply chain that covers ingredient sourcing, formulation and manufacturing. This structure gives the company involvement across several stages of product development and production.

The startup's model is built around the premise that nutrition products should be designed around the form of a nutrient, the dosage used and how the ingredient is delivered. Those factors can influence how a product is formulated, although individual health outcomes depend on the specific ingredient, dosage and supporting clinical evidence.

Clinical expertise and ingredient partnerships

Ace Blend says its products are developed by an in-house clinical team and recommended by a network of more than 400 doctors.

The company also states that clinical validation and automated testing are conducted independently by accredited laboratories in Europe. The source does not identify the laboratories or provide specific study results, so the scope of this validation cannot be independently assessed from the announcement alone.

Ace Blend works with global ingredient suppliers DSM and TCI. According to the company, these partnerships provide it with exclusive rights in India to certain technologies.

Access to specialised ingredients and delivery technologies could help the startup develop products that differ from conventional supplements. However, the commercial value of these arrangements will depend on the products launched, their performance and consumer demand.

The company also holds issued patents for new nutrition formats designed for everyday use. It expects the first products using these formats to reach the market in the fourth quarter of FY27.

Why the new funding matters

The $9.91 million Series A2 round will support further research-led product development and the introduction of new nutrition formats. These plans indicate that Ace Blend intends to expand its product portfolio while continuing to invest in its underlying formulation and manufacturing capabilities.

The timing is notable given the company's reported 300% growth in FY26 and its repeat-purchase figure of more than 46%. Repeat purchases can be an important indicator for consumer nutrition businesses because they may signal that customers are returning to products after their initial purchase.

Still, the available announcement does not disclose absolute revenue, profitability, customer acquisition costs or the contribution of individual product categories. Those details would help determine how efficiently the business is converting reported growth into a sustainable operation.

The participation of 3one4 Capital as the new round's lead investor and continued backing from Fireside Ventures provide fresh capital for the next stage of development. The company has not disclosed a detailed breakdown of how the funding will be allocated across research, manufacturing, marketing or distribution.

What comes next for Ace Blend

Ace Blend's next phase will depend on its ability to turn research and formulation work into commercially successful products. Its planned nutrition formats, expected in the fourth quarter of FY27, represent a future milestone for the company.

The startup will also need to maintain customer retention as it expands its range. In a market where consumers have many nutrition and supplement options, product quality, credible evidence, accessibility and repeat demand can all influence long-term performance.

For now, the funding gives Ace Blend additional resources to develop its research-led portfolio and bring new formats to market. Its reported growth provides a positive starting point, but future revenue disclosures, product launches and evidence of sustained customer demand will offer a clearer picture of its progress.